Short answer: Flecainide and metoprolol are used for different purposes in arrhythmia management. Flecainide is a rhythm-control drug (tries to restore/maintain normal rhythm, especially in atrial fibrillation without structural heart disease). Metoprolol is a rate-control/heart-protection drug (slows the heart rate and can help with conditions like hypertension, angina, or heart failure, and can also help in AF for rate control).
Key differences at a glance
- Drug class and mechanism
- Flecainide: Class Ic antiarrhythmic. Blocks fast sodium channels, slows conduction, can widen the QRS, mainly used to maintain sinus rhythm.
- Metoprolol: Beta-1 selective beta-blocker. Reduces heart rate and AV-nodal conduction, lowers blood pressure and myocardial oxygen demand.
- Primary indications
- Flecainide: Rhythm control in atrial fibrillation or other SVTs in patients without structural heart disease (no previous MI, no significant LV dysfunction, no severe CAD).
- Metoprolol: Rate control in atrial fibrillation, hypertension, ischemic heart disease, and heart failure with reduced ejection fraction (especially metoprolol succinate). Also used for angina, tachyarrhythmias, and postsurgical protection.
- Safety considerations and contraindications
- Flecainide:
- Contraindicated or used with great caution in structural heart disease, LV dysfunction, recent MI, or significant CAD due to risk of proarrhythmia and death.
- Can cause proarrhythmias, dizziness, blurred vision, QRS widening.
- Metoprolol:
- Can cause bradycardia, hypotension, fatigue; bronchospasm risk is lower than with nonselective beta-blockers but can occur at higher doses.
- Can worsen acute decompensated heart failure; generally beneficial in HFrEF when started/titrated carefully.
- May mask signs of hypoglycemia.
- Monitoring and safety checks
- Flecainide: Baseline ECG and echocardiogram to rule out structural heart disease; monitor QRS width and rhythm after starting or changing dose; watch for new arrhythmias.
- Metoprolol: Monitor heart rate and blood pressure; watch for excessive bradycardia; in heart failure, monitor symptoms, weight, and edema; adjust dose if combined with other rate-controlling or negative inotropic drugs.
- Dosing (very general ranges; actual dose depends on product and indication)
- Flecainide: Often 50 mg twice daily to 100-150 mg twice daily for maintenance (up to ~300 mg/day in some scenarios). Dosing is individualized and guided by rhythm response and ECG changes.
- Metoprolol (tartrate): Often 25-50 mg twice daily, titrating as needed.
Metoprolol succinate (extended-release): Commonly 25-100 mg once daily for hypertension; higher doses used in heart failure under specialist care.
Important: Dosing varies by product (tartrate vs succinate) and by indication; follow a clinician’s specific prescription.
When to choose one over the other (quick guide)
- Consider flecainide if:
- You have atrial fibrillation or SVT and no structural heart disease.
- You want to pursue rhythm control (maintain sinus rhythm), often after cardioversion.
- Consider metoprolol if:
- You need rate control in AF (to slow the ventricle response) or for other conditions (HTN, CAD, angina, HF with reduced EF).
- You have or are at risk of heart failure where beta-blockade can be beneficial (with appropriate monitoring).
Important cautions
- Flecainide is not for people with structural heart disease or significant LV dysfunction; using it in those patients can increase mortality.
- Metoprolol is not a rhythm-control drug; it won’t restore rhythm, but it helps control rate and protects the heart in certain conditions. It must be used carefully in HF or decompensated states.
Bottom line
- If your goal is to maintain a normal rhythm in AF and you don’t have structural heart disease, flecainide can be an option (with specialist oversight).
- If your goal is to control heart rate and manage other conditions (hypertension, angina, HF, CAD), metoprolol is often the appropriate choice.
- These drugs can sometimes be used together in AF management, but this should be guided by a clinician to avoid excessive bradycardia or interactions.
If you share a bit more about your situation (AF vs SVT, presence of heart disease, HF, blood pressure, asthma/CAD, current meds, pregnancy status), I can tailor the comparison and point out which option would be more appropriate and what monitoring would look like. And, as always, talk to your doctor before making any changes to medications.